GeneSight Mental Health Monitor Media Kit
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care
VideoThe GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted online by ACUPOLL Precision Research, Inc. from Aug. 16 – 30, 2022, among a statistically representative sample (n=1000) of adults age 18+. The survey included a representative sample of women diagnosed with depression and anxiety.
Previous releases
2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point,” Yet More than Half Wait a Year Before Seeking Treatment
April 26, 2022
Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns
New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey
December 15, 2021
Now is the time when people start to think of new year’s resolutions to improve their health. For many, the focus is on physical goals like losing weight or exercising more. A nationwide survey suggests that many may want to consider adding mental health resolutions to their list.
The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults
November 23, 2021
GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challenge
One of the biggest issues parents of teenagers may face is determining if their child is
experiencing a mental health challenge or ordinary “growing pains.”
Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey
October 11, 2021
Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won’t seek treatment for mental health conditions and others say they won’t get help until these symptoms take a toll in their lives.
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey
September 8, 2021
Depression medication trial and error is far too common – and may result in additional
mental health challenges.
New research reveals most Americans can’t identify the symptoms of depression
July 28, 2021
GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine,
today announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.
Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment
April 28, 2021
New poll shows 83% of people with depression agree life would be easier if others could understand their depression
In a new nationwide poll, the GeneSight® Mental Health Monitorfound that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, most people who have not experienced depression may not be able to understand the challenges, including its treatment.
Are you interested in taking the GeneSight test or becoming registered to provide the GeneSight test to your patients?
To help others understand how depression feels, click on the thumbnail below to visit a virtual experience.
For more information on the results of the survey or to conduct an interview with a patient living with anxiety, a healthcare provider or a GeneSight® expert, please email or call:
| Sharvari Dayal |
| sharvari.dayal@myriad.com |
| (330) 354-7150 |
| Cheryl Byrne |
| cheryl@rickmillercommunications.com |
| (978) 837-0371 |
Experiencing Depression
To help others understand how depression feels, click on the thumbnail below to visit a virtual experience.
